RESUMEN
In recent years, advances in medical diagnosis and treatment have greatly attracted our attention, whereas some rare diseases, such as leprosy, have not found a place in the medical education curriculum; their existence may even be forgotten. Although the prevalence and incidence rates for leprosy have been significantly reduced as a result of the control strategies of the World Health Organization, new cases still appear. A total of 214,783 new cases were reported from 143 countries during 2016, corresponding to the global new-case detection rate of 2.9 per 100,000 population. Leprosy proves to be a very interesting model due to its immunologic properties. It joins with syphilis, mycosis fungoides, cutaneous tuberculosis, and sarcoidosis as one of the great imitators. The diagnosis of leprosy can be simple and practical, but considering the diagnosis of leprosy in the differential diagnosis is the first requisite again.
Asunto(s)
Lepra , Animales , Diagnóstico Diferencial , Errores Diagnósticos/prevención & control , Quimioterapia Combinada , Diagnóstico Precoz , Femenino , Infecciones por VIH , Humanos , Periodo de Incubación de Enfermedades Infecciosas , Pruebas Intradérmicas/métodos , Lepromina , Leprostáticos/uso terapéutico , Lepra/diagnóstico , Lepra/tratamiento farmacológico , Lepra/inmunología , Lepra/patología , Masculino , Educación del Paciente como Asunto , Embarazo , Pruebas Serológicas , Piel/microbiología , Piel/patologíaRESUMEN
INTRODUCTION: Despite multidrug therapy, leprosy remains a public health issue. The intradermal Bacillus Calmette-Guérin (BCG) vaccine, Mitsuda test (lepromin skin test), and anti-phenolic glycolipid I (PGL-I) serology are widely used in leprosy studies and have shown great epidemiological value. METHODS: This longitudinal study evaluated the relative risks and benefits of these three tools by comparing results observed in household contacts (HHCs) of leprosy patients who developed leprosy with those of HHCs who did not in a population of 2,992 individuals monitored during a 10-year period. RESULTS: Seventy-five (2.5%) new leprosy cases were diagnosed, including 28 (0.9%) co-prevalent cases. Therefore, for the risk-benefit assessment, 47 (1.6%) HHCs were considered as truly diagnosed during follow-up. The comparison between healthy and affected contacts demonstrated that not only did BCG vaccination increase protection, but boosters also increased to 95% relative risk (RR) reduction when results for having two or more scars were compared with having no scars [RR, 0.0459; 95% confidence interval (CI), 0.006-0.338]. Similarly, Mitsuda reactions >7mm in induration presented 7-fold greater protection against disease development compared to reactions of 0-3mm (RR, 0.1446; 95% CI, 0.0566-0.3696). In contrast, anti-PGL-I ELISA seropositivity indicated a 5-fold RR increase for disease outcome (RR, 5.688; 95% CI, 3.2412-9.9824). The combined effect of no BCG scars, Mitsuda reaction of <7mm, and seropositivity to anti-PGL-I increased the risk for leprosy onset 8-fold (RR, 8.109; 95% CI, 5.1167-12.8511). CONCLUSIONS: The adoption of these combined assays may impose measures for leprosy control strategies.
Asunto(s)
Antígenos Bacterianos/inmunología , Vacuna BCG/inmunología , Trazado de Contacto/estadística & datos numéricos , Glucolípidos/inmunología , Lepra/inmunología , Adolescente , Adulto , Anciano , Niño , Preescolar , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Lactante , Recién Nacido , Lepromina/inmunología , Lepra/prevención & control , Lepra/transmisión , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Medición de Riesgo , Adulto JovenRESUMEN
Abstract: INTRODUCTION: Despite multidrug therapy, leprosy remains a public health issue. The intradermal Bacillus Calmette-Guérin (BCG) vaccine, Mitsuda test (lepromin skin test), and anti-phenolic glycolipid I (PGL-I) serology are widely used in leprosy studies and have shown great epidemiological value. METHODS: This longitudinal study evaluated the relative risks and benefits of these three tools by comparing results observed in household contacts (HHCs) of leprosy patients who developed leprosy with those of HHCs who did not in a population of 2,992 individuals monitored during a 10-year period. RESULTS : Seventy-five (2.5%) new leprosy cases were diagnosed, including 28 (0.9%) co-prevalent cases. Therefore, for the risk-benefit assessment, 47 (1.6%) HHCs were considered as truly diagnosed during follow-up. The comparison between healthy and affected contacts demonstrated that not only did BCG vaccination increase protection, but boosters also increased to 95% relative risk (RR) reduction when results for having two or more scars were compared with having no scars [RR, 0.0459; 95% confidence interval (CI), 0.006-0.338]. Similarly, Mitsuda reactions >7mm in induration presented 7-fold greater protection against disease development compared to reactions of 0-3mm (RR, 0.1446; 95% CI, 0.0566-0.3696). In contrast, anti-PGL-I ELISA seropositivity indicated a 5-fold RR increase for disease outcome (RR, 5.688; 95% CI, 3.2412-9.9824). The combined effect of no BCG scars, Mitsuda reaction of <7mm, and seropositivity to anti-PGL-I increased the risk for leprosy onset 8-fold (RR, 8.109; 95% CI, 5.1167-12.8511). CONCLUSIONS: The adoption of these combined assays may impose measures for leprosy control strategies.
Asunto(s)
Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Adulto Joven , Antígenos Bacterianos/inmunología , Vacuna BCG/inmunología , Trazado de Contacto/estadística & datos numéricos , Glucolípidos/inmunología , Lepra/inmunología , Ensayo de Inmunoadsorción Enzimática , Estudios Longitudinales , Lepromina/inmunología , Lepra/prevención & control , Lepra/transmisión , Medición de RiesgoRESUMEN
Leprosy is a chronic granulomatous disease caused by the bacillus Mycobacterium leprae. It primarily affects the skin and peripheral nerves and is still endemic in various regions of the world. Clinical presentation depends on the patient's immune status at the time of infection and during the course of the disease. Leprosy is associated with disability and marginalization. Diagnosis is clinical and is made when the patient has at least 1 of the following cardinal signs specified by the World Health Organization: hypopigmented or erythematous macules with sensory loss; thickened peripheral nerves; or positive acid-fast skin smear or skin biopsy with loss of adnexa at affected sites. Leprosy is treated with a multidrug combination of rifampicin, clofazimine, and dapsone. Two main regimens are used depending on whether the patient has paucibacillary or multibacillary disease.
Asunto(s)
Lepra , Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/inmunología , Antígenos Bacterianos/inmunología , Vacuna BCG , Vacunas Bacterianas , Quimioterapia Combinada , Salud Global , Glucolípidos/inmunología , Humanos , Pruebas Intradérmicas , Lepromina , Leprostáticos/administración & dosificación , Leprostáticos/efectos adversos , Leprostáticos/uso terapéutico , Lepra/clasificación , Lepra/diagnóstico , Lepra/tratamiento farmacológico , Lepra/epidemiología , Lepra/microbiología , Mycobacterium leprae/inmunología , Mycobacterium leprae/aislamiento & purificación , Mycobacterium leprae/fisiología , Pruebas Serológicas/métodos , Piel/microbiología , Piel/patología , Especificidad de la EspecieRESUMEN
BACKGROUND AND OBJECTIVE: Multidrug therapy in leprosy has failed to eliminate the problem of persister bacilli. Clearance of bacterial antigens is extremely slow which could predispose to continued nerve damage even after release from treatment. In the present study the immunomodulatory efficacy of BCG vaccine administered post-MDT in BL-LL leprosy patients was investigated in depth with a view to determining if augmenting chemotherapy with immunotherapy would help in faster clearance of M. leprae/antigens, bring down the level of persisters and minimise the occurrence/severity of reaction and nerve damage. METHODS: This is a placebo-controlled study in treated BL-LL patients. The patients are matched with respect to age, sex, bacteriological index and history of reaction, stratified and allocated to the two groups. One group (Gr A) received two doses of BCG-MOSCOW (3-33 x 10(5) cells) and the other (Gr B) normal saline (0.85%), injected intra-dermally at 3 month intervals. The Primary outcomes assessed at the end of 6 months were bacterial/antigen clearance, lepromin conversion, granuloma clearance and the occurrence of persisters. The secondary outcomes were clinical regression, occurrence and severity of reaction and changes in nerve functions. MATERIAL: A total of 107 BL-LL patients comprised of 49 in Gr A and 58 in Gr B; of which 36 and 42 respectively completed the study as per protocol, and are included in the final analysis. FINDINGS: The study findings show that both the primary and the secondary out comes were comparable in the two groups. Two doses of BCG administered post-MDT (Gr A) did not significantly alter the level of persisters or help in hastening the bacterial/antigen clearance, clinical regression of lesions and granuloma clearance. Lepromin conversion rates were also comparable. While the frequency of lepra reaction/neuritis following the intervention was comparable, the severity of reactions was significantly higher in Gr A. On the positive side neural functions assessed by nerve conduction studies showed that deterioration of motor nerve conduction was significantly lower in the BCG arm. Since all patients developing moderate to severe reactions, immediately received a course of corticosteroids, it is possible that timely use of it might have helped.
Asunto(s)
Vacuna BCG/uso terapéutico , Lepromina/inmunología , Leprostáticos/uso terapéutico , Lepra/tratamiento farmacológico , Lepra/inmunología , Mycobacterium leprae/inmunología , Tejido Nervioso/fisiología , Adolescente , Adulto , Vacuna BCG/efectos adversos , Quimioterapia Combinada , Femenino , Humanos , Inmunoterapia , Lepra/microbiología , Masculino , Persona de Mediana Edad , Tejido Nervioso/efectos de los fármacos , Adulto JovenRESUMEN
BACKGROUND: An early diagnostic test for detecting infection in leprosy is fundamental for reducing patients' sequelae. The currently used lepromin is not adequate for disease diagnosis and, so far, no antigen to be used in intradermoreaction has proved to be sensitive and specific for that purpose. Aiming at identifying new reagents to be used in skin tests, candidate antigens were investigated. METHODS: Random peptide phage display libraries were screened by using antibodies from leprosy patients in order to identify peptides as diagnostic reagents. RESULTS: Seven different phage clones were identified using purified antibodies pooled from sera of leprosy patients. When the clones were tested with serum samples by ELISA, three of them, 5A, 6A and 1B, allowed detecting a larger number of leprosy patients when compared to controls. The corresponding peptides expressed by selected phage clones were chemically synthesized. A pilot study was undertaken to assess the use of peptides in skin tests. The intradermal challenge with peptides in animals previously sensitized with Mycobacterium leprae induced a delayed-type hypersensitivity with peptide 5A (2/5) and peptide 1B (1/5). In positive controls, there was a 3/5 reactivity for lepromin and a 4/5 reactivity of the sensitized animals with soluble extract of M. leprae. CONCLUSIONS: The preliminary data suggest that may be possible to develop reagents with diagnostic potential based on peptide mimotopes selected by phage display using polyclonal human antibodies.
Asunto(s)
Antígenos Bacterianos/inmunología , Lepra/diagnóstico , Mycobacterium leprae/inmunología , Animales , Técnicas de Visualización de Superficie Celular , Epítopos/inmunología , Femenino , Cobayas , Humanos , Hipersensibilidad Tardía/inmunología , Lepromina/inmunología , Biblioteca de Péptidos , Péptidos/inmunologíaRESUMEN
Cynomolgus monkeys are a useful model for human tuberculosis, but susceptibility to M. leprae is unknown. A cynomolgus model of leprosy could increase understanding of pathogenesis-importantly, neuritis and nerve-damaging reactions. We administered viable Mycobacterium leprae to 24 cynomolgus monkeys by three routes, with a median follow-up period of 6 years (range = 1-19 years) involving biopsies, nasal smears, antiphenolic glycolipid-1 (PGL-1) antibody serology, and lepromin skin testing. Most developed evanescent papules at intradermal M. leprae inoculation sites that, on biopsy, showed a robust cellular immune response akin to a lepromin skin test reaction; many produced PGL-1 antibodies. At necropsy, four monkeys, without cutaneous or gross neurological signs of leprosy but with elevated PGL-1 antibodies, including three with nasal smears (+) for acid fast bacilli (AFB), showed histological features, including AFB, suggestive of leprosy at several sites. Overall, however, cynomolgus monkeys seem minimally susceptible to leprosy after experimental M. leprae administration.
Asunto(s)
Lepra/inmunología , Macaca fascicularis , Enfermedades de los Monos/microbiología , Mycobacterium leprae/inmunología , Animales , Anticuerpos Antibacterianos/sangre , Antígenos Bacterianos/inmunología , Biopsia/veterinaria , Modelos Animales de Enfermedad , Femenino , Glucolípidos/inmunología , Histocitoquímica/veterinaria , Lepromina , Lepra/microbiología , Masculino , Enfermedades de los Monos/inmunologíaRESUMEN
INTRODUÇÃO: A poliquimioterapia (PQT-OMS) para tratamento da hanseníase resultou em drástica redução da sua prevalência, mas em limitado impacto na detecção de casos novos (CN), que se manteve estável em Santa Catarina, estado na fase de pós-eliminação. Casos com altos índices baciloscópicos apresentam risco de recidiva tardia e podem consistir em focos persistentes de transmissão da doença. OBJETIVOS: Avaliar a recidiva da doença em amostra de pacientes virchowianos regularmente tratados com PQT-OMS 24 doses; ensaios de resistência terapêutica em camundongos para os casos suspeitos; resposta imune específica (celular e humoral) e detecção do DNA do M. leprae nos casos-índices (CI) e seus contatos indradomiciliares (CID); e os achados frente aos indicadores epidemiológicos e operacionais de Santa Catarina. CASUÍSTICA E MÉTODOS: A partir da busca no Sistema de Informação de Agravos de Notificação (SINAN), foram selecionados 46 CI, tratados entre 1990-2000, e 187 CID, dos municípios de Itajaí e Joinville. A avaliação constituiu de: exames dermatoneurológico e anatomopatológico da pele; baciloscopia do esfregaço cutâneo; reação de Mitsuda; sorologia para glicolipídeo fenólico-I (IgM-anti-PGL-I); ensaios de resistência terapêutica em camundongos e de detecção do DNA bacilar no muco nasal por reação em cadeia da polimerase (PCR) para as seqüências repetitivas específicas RLEP-130 e RLEP-372. RESULTADOS: Entre os CI após alta por cura (m=11,2 ± 3 anos), a idade média (57,3±14,5 anos) foi superior (p<0,05) comparada aos CID, com predomínio de homens (p=0,001) e Mitsuda-negativos (78,6%). Em quatro casos (8,7%) considerados recidivados, o valor sérico médio (0,365) e as freqüências da positividade do anti-PGL-I e a da RLEP-130 (75%; p=0,03) foram consistentemente elevados, e os testes em camundongos, negativos. Dentre os 187 CID, 22 (11,8%) adoeceram (CIDd), a maioria (10 casos; 45,4%) foi diagnosticada entre 2 a 19 anos; 6 casos (27,3%), no mesmo período do seu...
Introduction: Multidrugtherapy (MDT-WHO) resulted in marked reduction of leprosy prevalence in Brazil, without impact on detection of new cases in Santa Catarina (SC) state in the post-elimination phase. Lepromatous cases with high bacilloscopic index have late relapse risk and can consist in the disease transmission focus. Objectives: The aim of this study was to evaluate the disease recurrence and microbiological resistance in lepromatous leprosy patients regularly treated with MDT-WHO/24 doses; specific immune response (cellular and humoral) and M. leprae DNA detection in index cases (IC) and their household contacts (HHC); and the findings face to the epidemiological and operational indicators of Santa Catarina state. Casuistic and methods: After consulting the Brazilian Information System of Notification (SINAN) database, 46 IC successfully diagnosed and treated between 1990 and 2000, and their 187 HHC from Joinville and Itajaí (SC) municipalities were selected. A dermatoneurological examination was performed, as well as the skin biopsies for histopathology and therapy resistance assay in mouse pads, skin smears for bacilloscopy, anti-PGL-I IgM serology, Mitsuda reaction, polymerase chain reaction for M. leprae DNA detection in nasal secretion based on 130bp and 372bp specific repetitive sequences (RLEP). Results: Cured IC (m=11.2±3 years) had mean age higher ((57.3±14.5 years old; p<0.05) than HHC, most of them were males (p=0.001) and Mitsuda negative (78.6%). In 4 relapsed cases (8.7%) the average anti-PGL-I serum levels (0.365), as well as frequency of positive antibody and RLEP-130 (75%; p=0.03) were consistently high and the mouse footpads assays resulted negative. Among 187 HHC, 22 (11.8%) became sick (sHHC), 10 cases (45.4%) were diagnosed between 2 and 19 years, being 6 cases (27.3%) in the same year of their IC; 6 new cases (3 borderline-tuberculoid and 3 tuberculoid) were detected during the study, with high RLEP-130 positive frequency...
Asunto(s)
Humanos , Masculino , Femenino , Trazado de Contacto , Lepra/terapia , Lepromina , Mycobacterium leprae/aislamiento & purificación , Reacción en Cadena de la Polimerasa , Recurrencia , Lugares Marcados de Secuencia , Pruebas SerológicasRESUMEN
A proposta deste estudo foi identificar os alelos que codificam o HLA-DQ1 envolvidos na ausência de resposta imune celular em 60 pacientes hansenianos (50LL e 10BL) Mitsuda negativos. Os resultados obtidos mostraram a presença do alelo HLA-DQB1*0501 em 48.30% dos pacientes, seguido do HLA-DQB1*0602 em 31.66%, ambos subtipos do fenótipo HLA-DQB1*01. Apesar do predomínio destes alelos, não se pode afirmar que eles sejam os responsáveis pela ausência de resposta ao teste de Mitsuda. Sugerimos mais estudos neste segmento para a confirmação dos resultados.
The purpose of this study was to identify the gene encoding HLA-DQ1 involved in the absence of cellular immune response in 60 Mitsuda negative leprosy patients (50LL and 10BL). The results showed the presence of HLA-DQB1*0501 in 48.30% of patients, followed by HLA-DQB1*0602 in 31.66%, both subtypes of the phenotype HLA-DQB1*01. Despite the prevalence of these alleles, we can not say that they are responsible for the lack of response to the Mitsuda antigen. We suggest further studies to confirm the results.
Asunto(s)
Humanos , Antígenos HLA-DQ , Lepra Multibacilar/diagnóstico , Lepra/inmunología , Inmunidad Celular , Lepromina , Colonias de Leprosos , Pronóstico , Sistema Único de SaludRESUMEN
OBJECTIVES: The aim of the present work was to standardise a PCR-Restriction Fragment Length Polymorphism analysis (PRA) as a tool to detect the mycobacteriologic composition of lepromas from leprosy patients used in the production of lepromin to improve the quality of the Mitsuda test. DESIGN: PCR-Restriction Fragment Length Polymorphism analysis using hsp65 and rpoB genes were applied to 11 reference strains of mycobacteria, including M. leprae, and the obtained PRA profiles were compared to mycobacteria in clinical specimens. RESULTS: Out of the biopsies studied, 522% had DNA fragment amplified for both genes (hsp65 and rpoB) for M. leprae. However, other Mycobacterium species were observed in samples of lepromatous leprosy patients. Here we discussed the importance of mycobacteria identification in the antigen of Mitsuda production to be used in the evaluation of leprosy. CONCLUSIONS: Our results suggest that the use of the molecular approach for sample selection can contribute to an improvement in the quality of produced lepromin.
Asunto(s)
Dermatoglifia del ADN/métodos , Lepromina/aislamiento & purificación , Lepra/microbiología , Mycobacterium leprae/clasificación , Reacción en Cadena de la Polimerasa/métodos , Polimorfismo de Longitud del Fragmento de Restricción , Proteínas Bacterianas/genética , Técnicas de Tipificación Bacteriana/métodos , Técnicas de Tipificación Bacteriana/normas , Chaperonina 60 , Chaperoninas/genética , Análisis por Conglomerados , Dermatoglifia del ADN/normas , ARN Polimerasas Dirigidas por ADN/genética , Genotipo , Humanos , Lepra/patología , Mycobacterium leprae/genética , Mycobacterium leprae/aislamiento & purificación , Reacción en Cadena de la Polimerasa/normasRESUMEN
Delayed Type Hypersensitivity (DTH) and protective immunity are thought to be tightly linked. Remarkable similarity exists between their cellular and immune mechanisms. However, their dissociation is also well known. Here we investigate the immunological mechanisms relevant for their dissociation in a group of non-relapsing cured lepromatous leprosy (CLL) patients. In these patients, using lepromin reaction as a model system of DTH we report critical role of tissue chemokine response in synchronous manifestation of these linked phenomena. Results indicate elevation of the threshold of tissue chemokine induction thus dissociating DTH from protective immunity in lepromin -ive CLL patients. We also show that the DTH anergy in these subjects is not an absolute one but depends on the strength of the stimulus. Our data provide insights into the intricate relationship between DTH and immunity and highlight the persistent presence of effector immune mechanisms involving these two pathways in apparently unresponsive lepromatous leprosy patients.
Asunto(s)
Quimiocinas/inmunología , Hipersensibilidad Tardía/inmunología , Lepromina/inmunología , Lepra Lepromatosa/inmunología , Linfocitos T/inmunología , Quimiocinas/metabolismo , Humanos , Inmunidad/inmunología , Lepra Lepromatosa/microbiología , Activación de Linfocitos , Mycobacterium leprae/inmunologíaRESUMEN
Leprosy in Colombia is in the post-elimination phase; nevertheless, there are regions of this country where the incidence is still around 3-4/100,000. Early detection of leprosy patients is a priority for achieving control and elimination of leprosy; however, the clinical exam is not very sensitive and thus, the majority of patients are diagnosed only when they demonstrate lesions, and damage to the nerves and skin has already occurred. The goal of the present study was to identify Mycobacterium leprae infection and immune responses in household contacts (HHC) of leprosy patients from three prevalent regions of Colombia. Clinical examination, the Mitsuda test, evaluation of IgM anti-PGL-I in the serum, the bacillar index (BI), and polymerase chain reaction (PCR) from nasal swabs (NS) were performed for 402 HHC of 104 leprosy patients during a cross-sectional survey. Positive titers for IgM anti-PGL1 were found for 54 HHC, and PCR-positive NS for 22. The Mitsuda reaction was negative for 38 HHC, although three were positive for IgM anti-PGL-1 titers. The data document that leprosy transmission among HHC is still occurring in a non-endemic country.
Asunto(s)
Antígenos Bacterianos/sangre , Trazado de Contacto , Glucolípidos/sangre , Inmunoglobulina G/sangre , Lepra/diagnóstico , Mycobacterium leprae/inmunología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Colombia/epidemiología , Estudios Transversales , Ensayo de Inmunoadsorción Enzimática , Femenino , Encuestas Epidemiológicas , Humanos , Pruebas Intradérmicas , Lepromina , Lepra/epidemiología , Lepra/transmisión , MasculinoRESUMEN
Leprosy in Colombia is in the post-elimination phase; nevertheless, there are regions of this country where the incidence is still around 3-4/100,000. Early detection of leprosy patients is a priority for achieving control and elimination of leprosy; however, the clinical exam is not very sensitive and thus, the majority of patients are diagnosed only when they demonstrate lesions, and damage to the nerves and skin has already occurred. The goal of the present study was to identify Mycobacterium leprae infection and immune responses in household contacts (HHC) of leprosy patients from three prevalent regions of Colombia. Clinical examination, the Mitsuda test, evaluation of IgM anti-PGL-I in the serum, the bacillar index (BI), and polymerase chain reaction (PCR) from nasal swabs (NS) were performed for 402 HHC of 104 leprosy patients during a cross-sectional survey. Positive titers for IgM anti-PGL1 were found for 54 HHC, and PCR-positive NS for 22. The Mitsuda reaction was negative for 38 HHC, although three were positive for IgM anti-PGL-1 titers. The data document that leprosy transmission among HHC is still occurring in a non-endemic country.
Asunto(s)
Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Femenino , Humanos , Masculino , Antígenos Bacterianos/sangre , Trazado de Contacto , Glucolípidos/sangre , Inmunoglobulina G/sangre , Lepra/diagnóstico , Mycobacterium leprae/inmunología , Estudios Transversales , Colombia/epidemiología , Ensayo de Inmunoadsorción Enzimática , Encuestas Epidemiológicas , Pruebas Intradérmicas , Lepromina , Lepra/epidemiología , Lepra/transmisiónRESUMEN
No disponible
No disponible
Asunto(s)
Masculino , Persona de Mediana Edad , Humanos , Biopsia/métodos , Lepra Lepromatosa/complicaciones , Lepra Lepromatosa/diagnóstico , Lepra Lepromatosa/terapia , Lepromina , Reacción en Cadena de la Polimerasa/métodos , Rifampin/uso terapéutico , Dapsona/uso terapéutico , Clofazimina/uso terapéutico , Sensibilidad y Especificidad , Biopsia , Inmunidad Celular , Inmunidad Celular/fisiología , Mycobacterium leprae/aislamiento & purificación , Mycobacterium leprae/patogenicidadRESUMEN
Controversies over the vitamin D receptor (VDR) acting as a susceptibility factor in Mycobacterium sp. infections may be the result of incorrect population stratification. The risk of leprosy occurrence conditioned by VDR polymorphism was investigated by stratifying the population of a highly endemic Brazilian region into negative and positive Mitsuda responses. Leprosy patients (102) and a group of healthy nonconsanguineous household contacts (68) were genotyped for the VDR TaqI polymorphism (T/t). TT and Tt genotypes were not considered to be risk factors as their odds ratios (OR) were not different from those presented by the negative Mitsuda response individuals. The combination of the tt genotype and the negative Mitsuda test provided an occurrence rate 13 times higher in leprosy patients than in controls with positive Mitsuda responses. This suggests that there is a higher risk of leprosy development when individuals carry this unfavorable combination, and demonstrates a possible synergistic role of these two variables in leprosy susceptibility via effects on cellular immunity.
Asunto(s)
Lepromina/inmunología , Lepra/genética , Polimorfismo Genético , Receptores de Calcitriol/genética , Exones/genética , Predisposición Genética a la Enfermedad/genética , Genotipo , Humanos , Lepra/inmunología , Lepra/fisiopatología , Mycobacterium leprae/inmunología , Piel/inmunologíaRESUMEN
Hypersensitivity reactions called reversal reaction (RR) and erythema nodosum leprosum (ENL) occur in leprosy. They are characterized by an increase in tumor necrosis factor-alpha (TNF-alpha). Thalidomide is an effective treatment for ENL but not RR. Its effectiveness in ENL is attributed to inhibition of TNF-alpha, and this does not explain its failure to treat RR. We assessed thalidomide's effect on TNF-alpha in RR. Mononuclear cells from RR and non-RR patients and healthy individuals were treated with thalidomide and M.leprae (AFB), a cytosol fraction of M. leprae or Dharmendra lepromin. Thalidomide suppressed TNF-alpha, but when some RR patients' cells were stimulated with AFB, it enhanced TNF-alpha.
Asunto(s)
Leucocitos Mononucleares/efectos de los fármacos , ARN Mensajero/metabolismo , Talidomida/farmacología , Factor de Necrosis Tumoral alfa/biosíntesis , Adolescente , Adulto , Anciano , Antígenos Bacterianos/inmunología , Antígenos Bacterianos/farmacología , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Eritema Nudoso/tratamiento farmacológico , Eritema Nudoso/etiología , Eritema Nudoso/inmunología , Femenino , Humanos , Lepromina/inmunología , Lepromina/farmacología , Lepra/sangre , Lepra/complicaciones , Lepra/patología , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/metabolismo , Activación de Linfocitos/efectos de los fármacos , Masculino , Persona de Mediana Edad , Mycobacterium leprae/inmunología , Fitohemaglutininas/farmacología , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Factor de Necrosis Tumoral alfa/genéticaRESUMEN
Teniendo en cuenta lo expresado en la Declaración de Caracas, durante el desarrollo de la Tercera Conferencia Regional de la OPS/OMS sobre la Eliminación de la Lepra de las Américas, en la que se planteó como una necesidad el disponer de nuevas tecnologías apropiadas que permiten lograr un diagnóstico más temprano a fin de incluir sobre la transmisión hasta lograr la interrupción de la misma, se decidió poner en práctica esta experiencia de pesquisaje serológico en la Provincia de Camagüey; provincia que mantenía un endemia leprosa por encima del nivel de de eliminación como problema de salud con el objetivo de determinar el comportamiento clínico epidemiológico de la infestación por el Mycobacterium lepraen la Provincia de Camagüey durante los años 1999-2003. Se divide la intervención en tres etapas; en los años 1999-2000 se realiza el estudio de forma general en toda la provincia y de acuerdo a los resultados se decide hacer en los años 2001-2002 sólo a las personas residente en los municipios con prevalencia superior a 1 X 10.000, que residen en la cuadra y manzana donde se notificó un caso nuevo de Hansen. Con estos resultados se decide realizar la serología en el 2003 como norma a todas las personas que tienen relación con un caso nuevo de lepra y además seguir los positivos de serología por 5 años. Se realiza serología a 21.379 personas de población expuesta; de estas 768 personas con serologías positivas de Hansen (por encima del nivel de corte: valores > 0,300) a las que se les realiza baciloscopia, negativa o débil respuesta inmunológica (lepromina por debajo de 5 mm), o al repetir la serología a los 6 meses aumenta el titulo, sin lesiones cutáneas, no toma neural: tratamiento profiláctico con dapsona y rifampicina por 6 meses y seguimiento serológico cada seis meses por año. Si baciloscopia y lepromina, positivas o negativas, con lesiones cutáneas compatibles: casos (..) (AU)
No disponible
Asunto(s)
Humanos , Leprostáticos/uso terapéutico , Rifampin/uso terapéutico , Dapsona/uso terapéutico , Lepromina/sangre , Lepra/diagnóstico , Cuba/epidemiología , PrevalenciaRESUMEN
O tatu foi um modelo experimental importante para o estudo da hanseniase, alem de ser ainda uma importante fonte para coleta de bacilos. Apesar dos inumeros relatos de estudos em tatus de especie Dasypus novemcinctus, pouco se sabe sobre a real susceptibilidade desta especie ao bacilo de Hansen apos inoculaçao experimental com M. leprae. Alguns autores relatam que cerca de 80 por cento dos animais desenvolveriam a doença quando infectados. No Brasil, a inoculaçao experimental desta especie resultou em inoculaçoes positiva em apenas dois momento, tendo ate sido levantada a hipotese de estes animais serem mais resistentes a infecçao experimental. No presente estudo, utilizou-se a resposta ao nantigeno de Mitsuda como um indicador de resposta imune celular de tatus ao M. leprae...